Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS
NCT07770711 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2026-08-18
Summary
Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction. Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain. This randomized, controlled, open-label, parallel-group trial aims to compare the effects of a Mediterranean diet (MD) and a low-carbohydrate diet (LCD), each combined with metformin, inositol, or folic acid (active control), in obese women with PCOS and IR. A total of 102 participants will be randomly assigned to one of six intervention groups and followed for two months. Anthropometric measurements, body composition, biochemical parameters, and hedonic hunger will be assessed at baseline and after the intervention. The primary outcome is the change in insulin resistance, assessed by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), from baseline to 2 months. Secondary outcomes include changes in body composition, metabolic and biochemical parameters, and hedonic hunger.
Conditions
- PCOS (Polycystic Ovary Syndrome)
- Insulin Resistance
- Obesity (BMI>30)
Interventions
- DRUG
-
Metformin will be administered orally for 2 months. Treatment will begin at 500 mg once daily during the first week and will be increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated. Dose escalation is intended to improve gastrointestinal tolerability while achieving the target maintenance dose.
- DIETARY_SUPPLEMENT
-
İnositol
Myo-inositol will be administered orally as a powdered sachet formulation. Participants will receive two sachets daily for 2 months, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
- DIETARY_SUPPLEMENT
-
Folic Acid
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months. Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
- OTHER
-
Mediterranean diet
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months. Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss. The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat. Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
- OTHER
-
Low-Carbohydrate Diet
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months. Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss. The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates. After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements. Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
Sponsors & Collaborators
-
Dicle University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 40 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-08-20
- Primary Completion
- 2026-10-31
- Completion
- 2027-06-30
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
The Results of the Mediterranean Diet for PCOS
NCT06442189 ·Status: COMPLETED
-
Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women
NCT02910817 ·Status: COMPLETED ·Phase: NA
-
Metformin vs Inositol vs Diet vs Combination Therapy in PCOS
NCT07380841 ·Status: COMPLETED ·Phase: NA
-
Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
NCT07058675 ·Status: COMPLETED ·Phase: NA
-
Association of Vitamin D Status With Metabolic Markers in Adolescents With Polycystic Ovary Syndrome
NCT06970821 ·Status: COMPLETED
-
Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients
NCT00953355 ·Status: COMPLETED ·Phase: PHASE4
-
Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome
NCT01791647 ·Status: COMPLETED ·Phase: NA
-
Effects of Myo-inositol in Women With Polycystic Ovary Syndrome
NCT04892186 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
NCT03151005 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin Administration in Infertile Anovulatory PCOS Patients
NCT00501787 ·Status: WITHDRAWN ·Phase: PHASE4
-
Metformin in Patients With PCOS and Predictors of Poor Ovarian Response Ongoing In-vitro Fertilization
NCT01208740 ·Status: TERMINATED ·Phase: PHASE4
-
Intermittent Fasting (IF) Has Gained Recognition as a Promising Weight Loss Approach That Improves Body Weight, Insulin Resistance, and Metabolism. While Standard Diets Are Common in PCOS Management, IF May Address the Underlying Causes of Weight Gain and Offer Additional Metabolic Benefits
NCT06804044 ·Status: COMPLETED ·Phase: NA
-
Insulin Sensitizers Role in Control of PCOS Vicious Cycle.
NCT06170463 ·Status: COMPLETED ·Phase: PHASE1
-
Comparing the Effects of Oral Contraceptive Pills Versus Metformin
NCT03229057 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome
NCT07385716 ·Status: COMPLETED ·Phase: NA
-
Effects of a Ketogenic Diet on PCOS Outcomes
NCT04163120 ·Status: COMPLETED ·Phase: NA
-
Effect of Metformin on Patients With Polycystic Ovary Syndrome
NCT05802212 ·Status: COMPLETED ·Phase: NA
-
Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)
NCT01279512 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome
NCT00679679 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS
NCT00428311 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin in Infertile PCOS Patients
NCT00501904 ·Status: UNKNOWN ·Phase: PHASE4
-
Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome
NCT02802215 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
NCT01003483 ·Status: COMPLETED ·Phase: PHASE2
-
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
NCT01070160 ·Status: COMPLETED
-
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
NCT02500147 ·Status: TERMINATED ·Phase: PHASE4